Fig. 7

VS at Week 48 by baseline VL (a) and CD4⁺ (b) with DTG versus comparators. NRTI-unadjusted, FE model. *Indicates treatment comparisons are significantly different. ^†RPV is not indicated for patients with a VL > 100,000 copies/mL. Studies that reported data on CD4⁺ subgroups used a mix of cutoff inequalities (</≥, ≤/> and </> 200 cells/μL); the convention ≤/> 200 cells/μL used here reflects those used in the majority of studies. ATV/r, ritonavir-boosted atazanavir; BIC, bictegravir; Crl, credible interval; DTG, dolutegravir; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; EVG/c, cobicistat-boosted elvitegravir; FE, fixed effect; INSTIs, Integrase strand inhibitors; LPV/r, lopinavir-boosted ritonavir; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; OR, odds ratio; PIs, protease inhibitors; RAL, raltegravir; RPV, rilpivirine; VL, viral load; VS, virologic suppression